The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study
Open accessAbstract
Summary: Background: Empagliflozin is a sodium‐glucose‐cotransporter‐2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type‐2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS. Materials and methods: A randomized open‐label study was conducted in women with PCOS who were randomized to either empagliflozin 25 mg (n = 19) or metformin 1500 mg (n = 20) daily for 12 weeks. The main outcomes assessed were changes in anthropometric and body composition, hormonal and metabolic parameters. Results: Univariate analysis showed significant differences in weight (empagliflozin: −1.4 ± 3.2% vs metformin: 1.2 ± 2.3%; P = 0.006), body mass index (empagliflozin: −1.4 ± 3.2% vs metformin: 1.1 ± 2.2%; P = 0.006), waist circumference (empagliflozin: −1.6 ± 2.8% vs metformin: 0.2 ± 2.1%; P = 0.029) and hip circumference (empagliflozin: −2.0 ± 3.0% vs metformin: 1.1 ± 1.9%; P = 0.001), basal metabolic rate (empagliflozin: −1.8 ± 2.9% vs metformin: 0.1 ± 1.9%, P = 0.024) and fat mass (empagliflozin: −0.7 ± 4.9% vs metformin, 3.2 ± 5.0%; P = 0.023) between the empagliflozin and the metformin groups. These differences were confirmed in linear regression analysis after adjustment for relevant covariates. There were no significant changes in hormonal or metabolic parameters between both groups. Conclusion: There was a significant improvement in anthropometric parameters and body composition, in overweight and obese women with PCOS after 12 weeks of treatment with empagliflozin compared to metformin, although no changes were seen in hormonal or metabolic parameters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only a favourable effect of empagliflozin on body weight (empagliflozin –1.4 kg ± 3.2% vs. metformin: 1.2 kg ± 2.3%; p = 0.006) and BMI (empagliflozin: −1.4 ± 3.2% vs. metformin: 1.1 ± 2.2%; p = 0.006) has been observed.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
In the citing paper
“May be because of the short period of observation or the small sample size, no changes in metabolic parameters (insulin, fasting glucose, and HOMA‐IR) have been observed from the baseline, nor on hormonal profile for both drugs.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
In the citing paper
“May be because of the short period of observation or the small sample size, no changes in metabolic parameters (insulin, fasting glucose, and HOMA‐IR) have been observed from the baseline, nor on hormonal profile for both drugs.”
From From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management (2020) · cites this paper as [67]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740
Vallon, V., & Thomson, S. C. (2017) · Diabetologia · doi:10.1007/s00125-016-4157-3 · Cited by 635
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Mayoux, E., Kaneko, S., & Ota, T. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.05.028 · Cited by 512
Bolinder, J., Ljunggren, Ö., Johansson, L. O. M., Wilding, J. P. H., Langkilde, A., Sjöström, C. D., Sugg, J. E., & Parikh, S. J. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 492
Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-28 · Cited by 470
Combined oral contraceptives: venous thrombosis
de Bastos, M., Stegeman, B. H., Rosendaal, F. R., Vlieg, A. V. H., Helmerhorst, F. M., Stijnen, T., & Dekkers, O. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010813.pub2 · Cited by 416
SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
Inzucchi, S. E., Zinman, B., Wanner, C., Ferrari, R., FITCHETT, D. H., Hantel, S., Espadero, R.-M., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114559852 · Cited by 409
Tang, T., Glanville, J., Hayden, C. J., White, D., Barth, J. H., & Balen, A. H. (2006) · Human Reproduction · doi:10.1093/humrep/dei311 · Cited by 335
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Steven, S., Oelze, M. W., Hanf, A., Kröller‐Schön, S., Kashani, F., Roohani, S., Welschof, P., Kopp, M., Gödtel‐Armbrust, U., Xia, N., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.009 · Cited by 307
Morley, L. C., Tang, T., Yasmin, E., Norman, R. J., & Balen, A. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub6 · Cited by 296
Oelze, M. W., Kröller‐Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293
Shigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 255
Metabolic risk in PCOS: Phenotype and adiposity impact
Moran, L. J., Norman, R. J., & Teede, H. J. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.12.003 · Cited by 245
Morin-Papunen, L., Rantala, A. S., Unkila-Kallio, L., Tiitinen, A., Hippeläinen, M., Perheentupa, A., Tinkanen, H., Bloigu, R., Puukka, K., Ruokonen, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3061 · Cited by 243
Scheen, A. J. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0126-x · Cited by 237
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
Liakos, A., Karagiannis, T., Athanasiadou, E. A., Sarigianni, M., Mainou, M., Papatheodorou, K., Bekiari, E., & Τσάπας, Α. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12307 · Cited by 218
Yokono, M., Takasu, T., Hayashizaki, Y., Mitsuoka, K., Kihara, R., Muramatsu, Y., Miyoshi, S., Tahara, A., Kurosaki, E., Li, Q., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.01.040 · Cited by 195
Review: Role of metformin in the management of polycystic ovary syndrome
Lashen, H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380215 · Cited by 181
Metformin administration improves endothelial function in women with polycystic ovary syndrome
Diamanti‐Kandarakis, E., Alexandraki, K., Protogerou, A. D., Piperi, C., Papamichael, C. M., Aessopos, A., Lekakis, J., & Mavrikakis, M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01910 · Cited by 179
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Blonde, L., DAILEY, G. E., Jabbour, S. A., Reasner, C. A., & Mills, D. J. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003278 · Cited by 157
Mearns, E. S., Sobieraj, D. M., White, C. M., Saulsberry, W. J., Kohn, C. G., Doleh, Y., Zaccaro, E., & Coleman, C. I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125879 · Cited by 145
Liu, X., Zhang, N., Chen, R., Zhao, J., & Yu, P. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.011 · Cited by 137
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128
Briand, F., Mayoux, E., Brousseau, E., Burr, N., Urbain, I., Costard, C., Mark, M., & Sulpice, T. (2016) · Diabetes · doi:10.2337/db16-0049 · Cited by 118
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome
Sam, S., & Ehrmann, D. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4306-3 · Cited by 93
Approach to the Patient: Contraception in Women With Polycystic Ovary Syndrome
Yıldız, B. O. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3196 · Cited by 90
Amiri, M., Tehrani, F. R., Nahidi, F., Kabir, A., Azizi, F., & Carmina, E. (2017) · Metabolism · doi:10.1016/j.metabol.2017.05.001 · Cited by 70
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59
Patel, R., & Shah, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279597 · Cited by 47
Gallo, L. A., Ward, M. S., Fotheringham, A. K., Zhuang, A., Borg, D. J., Flemming, N., Harvie, B. M., Kinneally, T. L., Yeh, S.-M., McCarthy, D. A., et al. (2016) · Scientific Reports · doi:10.1038/srep28124 · Cited by 12
Flagged first, then by citations
Cited by
Sorted by citations
Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing
Sadeghi, H. M., Adeli, I., Calina, D., Docea, A. O., Mousavi, T., Daniali, M., Nikfar, S., Tsatsakis, A., & Abdollahi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020583 · Cited by 445
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 173
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T. F., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 180
Bednarz, K., Kowalczyk, K., Cwynar, M., Czapla, D., Czarkowski, W., Kmita, D., Nowak, A., & Madej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084334 · Cited by 148
Metadata
- Authors
- Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T.
- Affiliations
- University of Hull (GB)
- Pakistan Kidney and Liver Institute and Research Center (PK)
- Sidra Medical and Research Center (QA)
- Weill Cornell Medical College in Qatar (QA)
- Corresponding author
- Sathyapalan, Thozhukat
- ORCID
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2019-04-02
- Volume
- 90
- Issue
- 6
- Pages
- 805-813
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2922516009
- Cited by
- 121
- References
- 38
- Citations by year
- 2026: 12 · 2025: 20 · 2024: 18 · 2023: 20 · 2022: 22 · 2021: 16 · 2020: 11 · 2019: 1
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- Locations
- Clinical Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- Funders
- University of Hull
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- empagliflozin, polycystic ovary syndrome, metformin, SGLT2 inhibitors, body composition, weight loss, obesity, basal metabolic rate, fat mass, waist circumference, body mass index, insulin resistance, metabolic parameters, hormonal parameters, cardiovascular risk, women's health, drug comparison, anthropometry, SGLT1 inhibition, insulin sensitivity
- MeSH terms
- Adolescent, Adult, Anthropometry, Benzhydryl Compounds, Body Composition, Cardiovascular Diseases, Drug Administration Schedule, Female, Glucosides, Hormones, Humans, Life Style, Metformin, Middle Aged, Obesity, Polycystic Ovary Syndrome, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
